Table 4.

Cases and incidence (events per 100 000 patient–years) for 36 cancer types in the exposed and control cohorts

	Male				Female
	Exposed		Control		Exposed		Control
Patient–years follow‐up (10 5 )	3.005		5.444		3.510		6.324

	n	phtpy	n	phtpy	n	phtpy	n	phtpy
Primary outcomes
Prostate	450	138	1424	179	N/A
Colorectal	264	81	647	81	242	63	587	64
Endometrial	N/A				69	18	157	17
Ovarian	N/A				64	17	145	16
Pancreatic	42	13	115	14	68	18	136	15
Renal	26	8	56	7	25	6	29	3
MML	14	4	35	4	13	3	22	2
Pharyngeal	8	2	21	3	5	1	9	1
Thyroid	4	1	5	1	6	2	21	2
Secondary outcomes
Minor skin cancers	655	201	1635	205	629	163	1512	166
Breast	N/A				504	131	1103	121
Lung	314	96	701	88	231	60	485	53
Bladder	132	40	385	48	43	11	137	15
Carcinoma in situ	130	40	297	37	305	79	627	69
Oesophagus	89	27	185	23	42	11	117	13
Squamous cell carcinoma of skin	66	20	144	18	42	11	105	12
Stomach	62	19	141	18	38	10	99	11
Leukemia	37	11	114	14	28	7	62	7
Melanoma of skin	43	13	103	13	44	11	113	12
Non Hodgkin lymphoma	50	15	99	12	58	15	102	11
Other malignant neoplasm of skin	44	13	84	11	44	11	85	9
Myeloma	32	10	68	9	25	6	55	6
Mesothelioma	17	5	66	8	4	1	8	1
Other lymphatic and haemopoietic	28	9	62	8	32	8	71	8
Lip and oral cavity	29	9	61	8	18	5	41	5
Other respiratory organs	19	6	61	8	13	3	18	2
Other genitourinary organs	15	5	58	7	38	10	76	8
Other cancers	31	9	58	7	24	6	59	6
Liver	99	30	54	7	38	10	21	2
Liver a	35	14	41	7	8	3	15	3
Kidney	30	9	54	7	18	5	32	4
Other digestive organs	22	7	48	6	28	7	63	7
Nervous system	13	4	39	5	8	2	31	3
Other bone and connective tissue	11	3	17	2	13	3	27	3
Anus	5	2	8	1	3	1	15	2
Hodgkins lymphoma	5	2	7	1	3	1	11	1
Melanoma in situ	4	1	4	1	4	1	3	0

N/A Not applicable; MML, myelomonoblastic/myelomonocytic leukaemia’ phtpy, per 100 000 patient–years. We did not analyse a very small number of breast cancer cases in men.

^aExcluding patients exposed to >50 mg/day spironolactone and their controls. Events per 100 000 patient–years are rounded to nearest whole number